Bhabha Friyana K, McCormack Christopher, Campbell Belinda A, Lade Stephen, Buelens Odette, Van Der Weyden Carrie, Prince H Miles
Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Australas J Dermatol. 2023 May;64(2):194-203. doi: 10.1111/ajd.14016. Epub 2023 Mar 9.
The CD30-postive lymphoproliferative disorders, including lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma, account for up to 30% of all cutaneous T-cell lymphomas (CTCLs) and are the second most common form of CTCLs after mycosis fungoides. Both conditions differ in their clinical presentations; however, they share the expression of the CD30 antigen as a common immunophenotypic hallmark. There is a wide spectrum of management options depending on factors such as extent of disease, staging and treatment tolerability. This Clinical Practice Statement is reflective of the current clinical practice in Australia.
CD30 阳性淋巴增殖性疾病，包括淋巴瘤样丘疹病和原发性皮肤间变性大细胞淋巴瘤，占所有皮肤 T 细胞淋巴瘤（CTCL）的 30%，是仅次于蕈样肉芽肿的第二常见 CTCL 形式。这两种疾病临床表现不同；然而，它们都表达 CD30 抗原，这是一种共同的免疫表型特征。根据疾病范围、分期和治疗耐受性等因素，有多种管理选择。本临床实践声明反映了澳大利亚目前的临床实践。
